How eGFR drop after heart failure meds affects stopping those meds
Official title: Evaluation of the Impact of eGFR Decline on Clinical Practice Patterns of Medication Withdrawal in Heart Failure
Funded at Tufts Medical Center · NIH-11453636 · Data updated 2026-11-12
A small NIH grant will look at whether stopping heart failure medicines after a kidney function drop is safe for patients with heart failure.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $133,875 |
| NIH project number | 1R03DK145928-01A1 |
| Project ID | NIH-11453636 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with heart failure who are candidates for guideline-directed medical therapy and may experience an eGFR decline after starting GDMT.
✕Less likely to help
Patients not on GDMT or without eGFR changes related to GDMT initiation are less likely to benefit.
What this research studies
If a patient with heart failure experiences an early eGFR decline after starting medicines like RAAS inhibitors, MRAs, or SGLT2 inhibitors, doctors worry about stopping or lowering the dose. This project aims to understand whether continuing GDMT after an eGFR dip harms patients or whether stopping the medication might actually worsen heart failure outcomes. The study will analyze patterns of medication withdrawal and associated health effects in people with heart failure, focusing on real-world practice and outcomes. The goal is to clarify how clinicians should respond to eGFR declines to improve survival and reduce hospitalizations.
Why it matters
Potential benefit: If successful, the findings could guide clinicians on when to continue or adjust GDMT after an eGFR decline, potentially improving heart failure outcomes.
How similar studies have gone: Previous trials show GDMT benefits, but this study investigates real-world discontinuation practices and their consequences, which is relatively novel.
Where this research is happening
-
Tufts Medical Center
Boston, United States Active
Researchers
- Principal investigator: Mccallum, Wendy — Tufts Medical Center
- Study coordinator: Mccallum, Wendy
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.